Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

心脏纤维化和癌症治疗相关心脏毒性的风险预测

• 批准号: 9924641
• 负责人: Chetan N Shenoy
• 金额: $ 17.68万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9924641
• 关键词: Acute; Aftercare; Age; Anthracycline; Cancer Center; Cancer Patient; Cancer Survivor; Cardiac; Cardiac Myocytes; Cardiology; Cardiomyopathies; Cardiotoxicity; Cardiovascular Diseases; Cardiovascular system; Clinical; Clinical Investigator; Clinical Research; Comprehensive Cancer Center; Coronary Arteriosclerosis; Data; Degree program; Development; Development Plans; Diabetes Mellitus; Foundations; Functional disorder; Funding; Goals; Health; Health Care Costs; Heart Diseases; Heart failure; Hypertension; Incidence; Injury; Intervention; K-Series Research Career Programs; Left; Left Ventricular Dysfunction; Left Ventricular Ejection Fraction; Logic; Magnetic Resonance Imaging; Malignant Neoplasms; Measures; Mentors; Mentorship; Methods; Minnesota; Morbidity - disease rate; National Cancer Institute; Outcome; Patient Schedules; Patient risk; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Physicians; Play; Population; Positioning Attribute; Prevalence; Prevention; Prevention strategy; Preventive; Prospective cohort study; Radiation therapy; Research; Research Methodology; Research Personnel; Research Support; Resources; Risk; Risk Factors; Risk stratification; Role; Scientist; Structure; Testing; Time; Training; Trastuzumab; Treatment-Related Cancer; Troponin; Troponin I; Universities; Ventricular; Work; base; cancer risk; cancer therapy; cardiovascular disorder risk; career development; cohesion; coronary fibrosis; design; experience; high risk; improved; individual patient; individualized prevention; innovation; mortality; multidisciplinary; patient oriented; patient oriented research; patient stratification; prevent; programs; public health relevance; screening; skills; structural heart disease

 DESCRIPTION (provided by applicant): This Mentored Clinical Scientist Research Career Development Award proposal describes a five-year career development and training plan for Dr. Chetan Shenoy, a cardiovascular physician investigator at the University of Minnesota. His long-term goal is to be an independent, patient-oriented physician investigator who will make significant contributions in the field of preventive onco-cardiology. His career development plan encompasses the following: protected research time, focused didactic coursework within a Masters in Clinical Research degree program, hands-on training in cardiovascular prevention and advanced clinical research methodology, a highly structured cohesive mentoring program designed with a multidisciplinary team of accomplished clinical investigators, first-hand experience in patient-oriented research through the design and execution of a prospective cohort study initiated by Dr. Shenoy, and ultimately, successful application for independent research funding. Common cancer treatments such as anthracyclines and trastuzumab are associated with an increased risk of cardiotoxicity, which is responsible for significant mortality and morbidity in cancer survivors despite current preventive strategies. Identification of patients at risk for cancer treatment-related cardiotoxicity would allow us to intervene and prevent cardiovascular morbidity and mortality and improve the overall outcomes of patients with cancer. The overall objective of the proposed research is to establish the role of pre-existing cardiac fibrosis detected by magnetic resonance imaging to predict cardiotoxicity from cardiotoxic medications. In a prospective cohort study, Dr. Shenoy will first determine the prevalence and predictors of cardiac fibrosis in cancer patients before treatment with anthracyclines and/or trastuzumab. Next, he will determine the association between pre-existing cardiac fibrosis and cardiotoxicity at 24 months after initiation of anthracyclines and/or trastuzumab. Finally, he will determine the association between pre-existing cardiac fibrosis and cardiac troponin levels after initiation of anthracyclines and/or trastuzumab. This research will provide the first systematic data on the role of pre- existing cardiac fibrosis for the prediction f cardiotoxicity, laying the foundation for Dr. Shenoy's long-term goal of developing new interventions to prevent cardiovascular disease in patients with cancer. In summary, a comprehensive career development plan in the context of a well-defined training, research and mentorship structure will allow Dr. Shenoy to emerge as a highly successful, independent physician investigator in preventive onco-cardiology.

 描述（由申请人提供）：本指导临床科学家研究职业发展奖提案描述了明尼苏达大学心血管内科医生研究员 Chetan Shenoy 博士的五年职业发展和培训计划。他的长期目标是成为一名独立的、以患者为中心的医师研究者，为预防性肿瘤心脏病学领域做出重大贡献。他的职业发展计划包括以下内容：受保护的研究时间、临床研究硕士学位课程中的重点教学课程、心血管预防和先进临床研究方法的实践培训、由多学科优秀临床研究人员团队设计的高度结构化的有凝聚力的指导计划、通过设计和执行由 Shenoy 博士发起的前瞻性队列研究获得以患者为导向的研究的第一手经验，以及最终的成功 申请独立研究经费。蒽环类药物和曲妥珠单抗等常见癌症治疗方法会增加心脏毒性风险，从而导致显着死亡率 尽管目前采取了预防策略，但癌症幸存者的发病率仍然很高。识别患者 存在与癌症治疗相关的心脏毒性的风险将使我们能够干预和预防心血管发病率和死亡率，并改善癌症患者的总体结果。拟议研究的总体目标是确定磁共振成像检测到的预先存在的心脏纤维化在预测心脏毒性药物的心脏毒性方面的作用。在一项前瞻性队列研究中，Shenoy 博士将在接受蒽环类药物和/或曲妥珠单抗治疗之前首先确定癌症患者心脏纤维化的患病率和预测因素。接下来，他将在开始使用蒽环类药物和/或曲妥珠单抗后 24 个月确定先前存在的心脏纤维化与心脏毒性之间的关联。最后，他将确定开始使用蒽环类药物和/或曲妥珠单抗后，先前存在的心脏纤维化与心肌肌钙蛋白水平之间的关联。这项研究将提供关于预先存在的心脏纤维化在预测心脏毒性中的作用的第一个系统数据，为 Shenoy 博士开发新的干预措施来预防癌症患者心血管疾病的长期目标奠定基础。总之，在明确的培训、研究和指导结构背景下制定的全面职业发展计划将使 Shenoy 博士成为预防性肿瘤心脏病学领域非常成功的独立医师研究者。

项目成果

Sex-Specific Stress Perfusion Cardiac Magnetic Resonance Imaging in Suspected Ischemic Heart Disease: Insights From SPINS Retrospective Registry.

疑似缺血性心脏病的性别特异性应激灌注心脏磁共振成像：来自 SPINS 回顾性登记的见解。

• DOI: 10.1016/j.jcmg.2022.11.025
• 发表时间: 2023
• 期刊: JACC. Cardiovascular imaging
• 作者: Heydari,Bobak;Ge,Yin;Antiochos,Panagiotis;Islam,Sabeeh;Steel,Kevin;Bingham,Scott;Abdullah,Shuaib;Mikolich,JRonald;Arai,AndrewE;Bandettini,WPatricia;Patel,AmitR;Shanbhag,SujataM;Farzaneh-Far,Afshin;Heitner,JohnF;Shenoy,Ch
• 通讯作者: Shenoy,Ch

Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help?

识别可受益于植入式心律转复除颤器的非缺血性心肌病患者：心血管磁共振成像的晚期钆增强有帮助吗？

• DOI: 10.1016/j.ahj.2019.12.010
• 发表时间: 2020
• 期刊: American heart journal
• 影响因子: 4.8
• 作者: Kalra,Rajat;Shenoy,Chetan
• 通讯作者: Shenoy,Chetan

Left Ventricular Noncompaction and Cardiogenic Shock.

• DOI: 10.1161/circulationaha.119.043716
• 发表时间: 2020-02
• 期刊: Circulation
• 影响因子: 37.8
• 作者: Felipe Kazmirczak;Cindy M. Martin;C. Shenoy

Chest Pain and a Very Abnormal Stress Echocardiogram.

胸痛和非常异常的负荷超声心动图。

• DOI: 10.1161/circulationaha.118.033885
• 发表时间: 2018
• 期刊: Circulation
• 影响因子: 37.8
• 作者: Reddy,Prajwal;Birkenbach,Mark;Shenoy,Chetan
• 通讯作者: Shenoy,Chetan

Imaging of Clinically Unrecognized Myocardial Fibrosis in Patients With Suspected Coronary Artery Disease.

• DOI: 10.1016/j.jacc.2020.06.063
• 发表时间: 2020-08-25
• 期刊: Journal of the American College of Cardiology
• 影响因子: 24
• 作者: Antiochos P;Ge Y;Steel K;Bingham S;Abdullah S;Mikolich JR;Arai AE;Bandettini WP;Patel AR;Farzaneh-Far A;Heitner JF;Shenoy C;Leung SW;Gonzalez JA;Shah DJ;Raman SV;Ferrari VA;Schulz-Menger J;Stuber M;Simonetti OP;Kwong RY;SPINS Study Investigators
• 通讯作者: SPINS Study Investigators